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Lafora disease (LD), the most devastating adolescence-onset epilepsy, is caused by 
mutations in the EPM2A or EPM2B genes, which encode the proteins laforin and malin, 
respectively. Loss of function of one of these proteins, which are involved in the regulation 
of glycogen synthesis, induces the accumulation of polyglucosan bodies (PGBs)—known 
as Lafora bodies (LBs) and associated with neurons—in the brain. Ageing and some 
neurodegenerative conditions lead to the appearance of another type of PGB called 
corpora amylacea, which are associated with astrocytes and contain neo-epitopes that can 
be recognized by natural antibodies. Here we studied the PGBs in the cerebral cortex and 
hippocampus of malin knockout mice, a mouse model of LD. These animals presented not 
only LBs associated with neurons but also a significant number of PGBs associated with 
astrocytes. These astrocytic PGBs were also increased in mice from senescence-
accelerated mouse-prone 8 (SAMP8) strain and mice with overexpression of Protein 
Targeting to Glycogen (PTGOE), indicating that they are not exclusive of LD. The astrocytic 
PGBs, but not neuronal LBs, contained neo-epitopes that are recognized by natural 
antibodies. The astrocytic PGBs appeared predominantly in the hippocampus but were also 
present in some cortical brain regions, while neuronal LBs were found mainly in the brain 
cortex and the pyramidal layer of hippocampal regions CA2 and CA3. Our results indicate 
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Main points 
• Absence of malin triggers the formation of polyglucosan bodies in neurons and 
enhances their development in astrocytes.  
• These astrocytic polyglucosan bodies contain neo-epitopes that are recognized by 
natural antibodies. 









The term “polyglucosan bodies” (PGBs) refers to complex molecular aggregates composed 
of relatively large glucose polymers reaching diameters of tens of micrometres. PGBs have 
been reported in the central nervous system, but also in other organs and tissues, such as 
heart, skeletal muscle and liver (Cavanagh, 1999). While these aggregates have been 
described in humans and other species, they have been most widely studied in mammals. 
Various forms of PGB are linked to specific diseases. For example, corpora amylacea (CA) 
accumulate in the human brain during normal aging and to a greater extent in several 
neurodegenerative conditions, including Alzheimer’s, Parkinson’s, Huntington’s and Pick’s 
diseases (Pirici and Margaritescu, 2014; Rohn, 2015). Although human brain CA are 
formed mainly by aggregates of polymerized glucose, the presence of waste elements is a 
recurrent feature of these structures. This observation suggests that that they are involved 
in the trapping and sequestration of potentially hazardous products (Cavanagh, 1999; Pirici 
and Margaritescu, 2014; Rohn, 2015). We recently demonstrated that brain CA contain a 
number of neo-epitopes (Augé et al., 2017). The neo-epitopes are specific epitopes that are 
not present in healthy brain structures but appear in situations of cellular stress and tissue 
damage (Binder, 2010). We also found that the neo-epitopes present in CA are recognized 
by natural IgM antibodies, thus revealing the potential role of the natural immune system in 
CA removal (Augé et al., 2017). That study of the interaction between CA and the natural 
immune system was based on previous findings obtained in mice (Manich et al., 2015; 
Manich et al., 2016). In the same way in which CA accumulate with age in the human brain, 
aging in the mouse brain leads to the progressive appearance of PGBs, these generally 
referred to as  “PAS granules” because of their positive staining with Periodic acid-Schiff 
(PAS). Given that the term “PAS granules” used to describe these mouse inclusions leads 
to misinterpretation because all PGBs are stained by PAS, in the present study we refer to 
them as CA-like (CAL) granules, because of their similarities to the CA of the human brain. 
CAL granules are present in a wide range of mouse strains, but they are particularly 
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abundant in the senescence-accelerated mouse prone 8 (SAMP8) model (Manich et al., 
2016). The SAMP8 model is a non-genetically modified strain of mice with a characteristic 
accelerated aging process that shares characteristics with aged humans, such as a 
reduced lifespan, lordosis, hair loss, and reduced physical activity (Hamamoto et al., 1984; 
Takeda et al., 1994). In these animals, CAL granules appear in various regions of the brain 
as early as three months of age, and their number increases faster than in other strains 
(Del Valle et al., 2010; Jucker et al., 1994a, 1994b; Kuo et al., 1996). CAL granules arise 
from a degenerative process that affects astrocytic processes and their surrounding 
neuropil, and the granules are organized into clusters, each one associated with a specific 
astrocyte (Manich et al., 2014a). As observed for CA, some neo-epitopes appear during 
CAL granule formation (Manich et al., 2014b), and they are recognized by natural IgMs 
(Manich et al., 2015; Manich et al., 2016). We also found that many commercial antibodies 
are contaminated with natural IgMs, thus leading to false positive staining in 
immunohistochemical studies of CAL granules in mice (Manich et al., 2014b; Manich et al., 
2016) and of CA in the human brain (Augé et al., 2017). These false positive 
immunostainings contribute to explaining the controversial results of research addressing 
CA and CAL granules and reveal the need to re-examine many of the immunohistochemical 
studies carried out to date. 
 
Human diseases like Adult Polyglucosan Body Disease (APBD) and Lafora disease (LD) 
are also characterized by the accumulation of PGBs in the brain (Cavanagh, 1999; Pirici 
and Margaritescu, 2014). LD, the most devastating form of adolescence-onset epilepsy, is 
perhaps the most striking example of the accumulation of PBGs in this organ. These PGBs 
are referred to as Lafora bodies (LBs). LBs are formed by abnormal poorly branched 
glycogen that aggregates and amasses into large neuronal inclusions over time (Duran and 
Guinovart, 2015). LB deposition in the brain leads to the onset and inexorable worsening of 
neurodegeneration and epilepsy, leading to death by early adulthood (Cavanagh, 1999; 
Minassian, 2001; Pirici and Margaritescu, 2014). LD is an autosomal recessive myoclonus 
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epilepsy caused by mutations in one of the following two genes: EPM2A, which encodes 
laforin, a dual-specificity protein phosphatase with a functional carbohydrate-binding 
domain (Minassian et al., 1998; Serratosa et al., 1999); and EPM2B, which encodes malin, 
an E3 ubiquitin ligase (Chan et al., 2003). Individuals with mutations in EPM2A or EPM2B 
are neurologically and histologically indistinguishable. Laforin can function as a glucan 
phosphatase, removing the phosphate groups attached to glycogen (Tagliabracci et al., 
2007). This finding, along with the hyperphosphorylation of glycogen in laforin knockout 
mice (laforin KO), led to the hypothesis that elevated levels of phosphate esters cause the 
abnormal glycogen structure and trigger LB formation (Roach, 2015; Tagliabracci et al., 
2008). However, the phosphatase activity of laforin does not appear to be required to 
prevent the disease (Gayarre et al., 2014), and glycogen hyperphosphorylation does not 
cause the formation of LBs (Nitschke et al., 2017). Also, there is evidence that laforin and 
malin form a complex, and these proteins have been described to regulate glycogen 
accumulation through proteasome-dependent control of glycogen-related proteins, such as 
Protein Targeting to Glycogen (PTG) (Vilchez et al., 2007; Worby et al., 2008), Muscle 
Glycogen Synthase (MGS) (Vilchez et al., 2007) and glycogen debranching enzyme 
(Cheng et al., 2007). In addition, it has been reported that laforin and malin are involved in 
the clearance of misfolded proteins through the ubiquitin–proteasome system (Garyali et 
al., 2009; Rao et al., 2010) and in the autophagy degradation pathway (Aguado et al., 2010; 
Criado et al., 2012; Knecht et al., 2010; Puri et al., 2012). In previous studies, we generated 
a malin knockout mouse (malinKO) as a model of LD, and combined it with a mouse with a 
specific deletion of MGS in the brain (MGSKO) (Duran et al., 2013), to generate a double 
malinKO+MGSKO mouse. We observed that malinKO animals accumulate LBs in the brain 
and other tissues and show neurodegeneration and functional impairments, including 
disrupted autophagy (Vallés-Ortega et al., 2011; Duran et al., 2014). The malinKO+MGSKO 
mouse did not show the accumulation of LBs, neurodegeneration or autophagy impairment 
seen in the malinKO animals (Duran et al., 2014), thereby suggesting that all these defects 
are a consequence of glycogen accumulation. Moreover, mice overexpressing PTG 
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(PTGOE), in which GS activity is increased, present high accumulation of PGBs in the brain 
(Duran et al., 2014). It is remarkable that although accumulations of CA have been 
described in several neurodegenerative conditions, including Alzheimer’s, Parkinson’s, 
Huntington’s and Pick’s diseases, the studies of PGBs in LD are centered in neuronal LBs, 
and the presence of astrocytic CAL granules in mouse models of LD has not yet been 
studied. 
 
In this study, we explore, on the one hand, the presence of astrocytic CAL granules in the 
brain of a mouse model of LD, with the aim to determine whether this disease is 
characterized not only by altered neuronal function but also by the involvement of 
astrocytes. On the other hand, we address whether the LBs present in LD contain neo-
epitopes that are recognized by natural IgMs. To this end, we used malinKO mice and 
compared them with mice from other strains or models, such as SAMP8, MGSKO and 








Materials and methods 
 
Mice 
MalinKO, PTGOE and MGSKO mice were generated as previously described (Duran et al., 
2014). After weaning, at 3 weeks of age, tail clippings were taken for genotyping by qPCR 
(performed by Transnetyx). Wild-type littermates from the different colonies were used as 
controls. SAMP8 mice were obtained from the Servei d’Estabulari de la Facultat de 
Farmàcia i Ciències de l’Alimentació (Universitat de Barcelona). All procedures were 
approved by the Barcelona Science Park’s Animal Experimentation Committee and the 
Ethical Committee for Animal Experimentation of the Universitat de Barcelona and were 
carried out in accordance with the European Community Council Directive and National 
Institutes of Health guidelines for the care and use of laboratory animals. Mice were 
maintained on a 12/12 h light/dark cycle under standard room temperature (RT) and 
allowed free access to a commercial chow diet and water throughout the study. All 
experiments were performed with animals aged between 60 and 80 weeks (n=4 for each 
experimental group).  
 
Brain processing 
Frozen or paraffin-embedded brain sections were used. To obtain frozen sections, animals 
were anesthetized intraperitoneally with sodium pentobarbital (80 mg/kg) and given an 
intracardiac gravity-dependent perfusion of 50 mL of saline solution. Brains were dissected 
and frozen by immersion in isopentane and then chilled in dry ice. Frozen brains were then 
cut at the coronal plane into 20-μm-thick sections on a cryostat (Leica Microsystems, 
Germany) at −22°C and placed on slides. Coronal sections from bregma around −2.30 
were selected, and the studies were performed considering the hippocampus and the 
cortex located between the retrosplenial granular region and the primary somatosensory 
cortex as the regions of interest. Sections were fixed with acetone for 10 min at 4°C and 
frozen at −20°C. To obtain paraffin-embedded sections (used in PTGOE mice), animals were 
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perfused transcardially with phosphate-buffered saline (PBS) containing 4% of 
paraformaldehyde (PF). Brains were removed, postfixed overnight with PBS 4% PF, and 
embedded in paraffin. Paraffin sections were then cut to a thickness of 5 μm in a 
microtome. 
 
PAS staining  
Frozen sections were stained with PAS following the standard procedure. Briefly, sections 
were fixed for 10 min in Carnoy’s solution (60% ethanol, 30% chloroform and 10% 
glacial acetic acid). The slides were then pretreated for 10 min with 0.25% periodic acid 
(19324-50, Electron Microscopy Sciences) in distilled water, followed by a washing step for 
3 min with distilled water. They were then immersed in Schiff’s reagent (26052-06, Electron 
Microscopy Sciences) for 10 min. Next, the slides were washed for 5 min in distilled water. 
Nuclei were counterstained for 1 min with a hematoxylin solution following Mayer (3870, 
J.T. Baker, Center Valley, USA). The slides were then washed, dehydrated with xylene, and 
coverslipped with quick-mounting medium (Eukitt, Fluka Analytical, Germany). 
 
Immunofluorescence  
Frozen sections were rehydrated with PBS and then blocked and permeabilized with 1% 
bovine serum albumin (Sigma-Aldrich) (Blocking buffer, BB) and 0.1% Triton X-100 (Sigma-
Aldrich) in PBS for 20 min. They were washed with PBS and incubated with the 
corresponding primary antibodies overnight at 4ºC. Slides were washed and incubated for 1 
h at RT with the corresponding secondary antibodies. Nuclear staining was performed with 
Hoechst (H-33258, Fluka, Madrid, Spain), and slides were washed and coverslipped with 
Fluoromount (Electron Microscopy Sciences, Hatfield, PA, USA). 
 
PF-paraffin-embedded sections were deparaffinized and required an antigen retrieval step 
before immunostaining. Thus, slides were immersed in sodium citrate buffer (10 mM, 
pH=6.0) heated to 100°C for 40 min and then cooled to RT for 30 min. The slides were 
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washed, and the permeabilization step and immunofluorescence were then performed as 
described for the frozen sections. 
 
The following were used as primary antibodies: rabbit monoclonal against GS (#15B1, Cell 
Signaling, Leiden, Netherlands); mouse monoclonal IgG1 against NeuN (#MAB377, 
MerckMillipore, Darmstadt, Germany); chicken polyclonal against GFAP (#AB5541, 
MerckMillipore); mouse monoclonal IgG2a against p62 (#ab56416, Abcam, Cambridge, 
UK); and human IgM purified immunoglobulins (OBT1524; AbD Serotec, Kidlington, UK). 
The following were used as secondary antibodies: Alexa Fluor (AF) 488 donkey anti-rabbit 
IgG (H+L); AF555 donkey anti-rabbit IgG (H+L); AF488 goat anti-chicken IgG (H+L); AF594 
goat anti-mouse IgG1; AF594 goat anti-mouse IgG2a; and AF488 goat anti-human IgM 
heavy chain (Life Technologies, Eugene, OR, USA). 
 
Staining controls were performed by incubating brain sections with BB instead of the 
primary antibody. In double staining, antibody cross-reactivity controls were also performed. 
In the case of p62 and GS staining, and in order to discard possible false positive staining 
produced by the presence of contaminant IgMs in the vials, secondary incubations with 
AF488  goat anti-mouse IgM (Jackson ImmunoResearch Laboratories) or goat anti-rabbit 
IgM conjugated to fluorescein isothiocyanate (FITC) (Abcam) antibodies were performed. 
 
Image acquisition 
Images were taken with a fluorescence laser and optic microscope (BX41, Olympus, 
Germany) and stored in tiff format. In immunofluorescence studies, and for each staining, 
all images were acquired using the same microscope, laser and software settings. Image 
treatment and analysis were performed by means of the ImageJ program (National Institute 





Quantification of the density of the different types of PGBs in mouse brain  
To quantify the density of the different types of PGB (i.e. neuronal LBs (nLBs) and CAL 
granules) in the brains of mice from different strains, a minimum of four animals from each 
strain were used. Images of coronal sections were obtained with a Hamamatsu 
NanoZoomer Digital Slide Scanner (40× magnification). From each scanned coronal 
section, we then exported two tiff images containing the left and right brain hemispheres, 
each image including the hippocampus and the cortex from the retrosplenial granular region 
to the primary somatosensory cortex. The tiff images were then processed to calculate the 
number of nLBs or CAL granules using the ImageJ program (National Institute of Health, 
USA). For each tiff image, the process performed by this program included the following: a) 
splitting the color channels in order to obtain the green channel; b) transforming this new 
image into an 8-bit image; c) establishing the threshold in order to binarize the image; d) 
binarizing the image; d) applying the watershed; e) selecting, in the original image, the 
region where granules will be counted, i.e. the Region of Interest (ROI); f) saving the ROI in 
the ROI manager; g) applying the saved ROI in the corresponding binarized image; and h) 
to count the particles (i.e. PGBs) contained in the ROI. An example of image treatment and 
quantification of granules is summarized in Figure S1 (Supplementary material). To perform 
the quantification in non-continuous regions, we used the “combine” option in the ROI 
manager. The green channel of the original image was selected because it allowed better 
differentiation of the PGBs from other structures, such as nuclei and vessels walls. The 
threshold was visually and accurately set on each image, obtaining the best discrimination 
of granules. Watershed was applied because it allowed us to split some granules that were 
fused on binarized images. The size of particles to be counted was limited, in order to 
discard large structures. After the entire process, for each tiff image, we obtained the 
number of CAL granules in the hippocampus and in the cortex and that of nLBs in each of 
these regions in the case of malinKO mice (nLBs are present only in malinKO mice, not in the 
other strains studied). Finally, to obtain an approximation of the density of CAL or nLBs in a 
given hippocampal or cortical region, the total number of granules was divided by the total 
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volume (area of the hippocampal or cortical region x section thickness). Data were 
tabulated for further descriptive and statistical analysis.  
 
Measurement of PGB size 
To determine the size of the different types of PGB (i.e. nLBs and CAL granules) in malinKO 
animals, representative images from the brain cortex stained with the PAS method were 
acquired at a 40x magnification with a BX41 Olympus microscope (Germany). Four animals 
were used, and four images were acquired for each animal. The diameter of the PGBs in 
the images was then manually measured using the “straight” tool of the ImageJ program 
(National Institute of Health, USA). Data were tabulated for further descriptive and statistical 
analysis.  
 
Statistical analysis  
Statistical analysis was performed with the ANOVA module of the IBM SPSS Statistics (IBM 
corp.©). Scheffe test was used for post-hoc comparisons. Significant differences were 







MalinKO mice accumulate two types of PGB 
To characterize and differentiate PGBs in mouse brain, several immunostainings were 
performed in control, malinKO and SAMP8 brain sections from animals aged 60-80 weeks. 
To detect PGBs, an antibody directed against GS, the only enzyme able to synthesize 
glucose polymers in mammals and a marker of PGBs (Vallés-Ortega et al. 2011), was 
used. Simultaneous fluorescence immunostaining on hippocampal sections with anti-GS 
and anti-GFAP antibodies allowed observation of the PGBs (Figure 1). As expected from 
previous descriptions (del Valle et al., 2010; Manich et al., 2016), a high number of 
astrocytic CAL granules were observed in SAMP8 mice (Figure 1a). These bodies were 
abundant in the hippocampus and tended to form clusters. The granules were in contact 
with astrocytic processes, as shown by GFAP staining, and, occasionally, the whole 
astrocyte that formed the cluster of granules was clearly visible. As previously indicated, 
CAL granules carry some neo-epitopes that are recognized by natural IgM antibodies, and 
the presence of these IgMs as contaminants in commercial antibodies has led to false 
positive staining and misinterpretations (Manich et al., 2015). In the present work, in order 
to discard false positive staining produced by such contaminant IgMs in the vial of anti-GS 
obtained in rabbit, we stained some sections with anti-GS as a primary antibody and a 
fluorochrome-labeled anti-rabbit IgM as a secondary antibody. The absence of staining on 
astrocytic CAL granules indicated that the anti-GS vial did not contain IgMs (Supplementary 
material, Figure S2), and thus confirmed that the GS staining of CAL granules was specific 
and not caused by IgMs. Of note, malinKO brain sections double immunostained with anti-
GS and anti-GFAP also contained clusters of astrocytic CAL granules, which were 
distributed in practically all hippocampal layers (Figure 1b), while these clusters were 
observed only sporadically in the hippocampus of control animals (Figure 1c). In addition, 
the hippocampus of malinKO mice showed some PGBs that differed from CAL granules. 
These PGBs were located in the hippocampal pyramidal layer mainly of the CA2-CA3 
region and were adjacent to nuclei, presumably neuronal nuclei (Figure 1b). These PGBs 
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were spherical and appeared to be larger than astrocytic CAL granules, they did not form 
clusters, and they were unrelated to GFAP processes. SAMP8 and control animals did not 
present this second type of PGB. The PGBs that differed from astrocytic CAL granules 
were also detected in the brain cortex of malinKO mice (Figure 1e) but not in the cortex of 
control or SAMP8 animals (Figures 1d and f). In contrast, sporadic clusters of astrocytic 
CAL granules were detected in the cortex of the malinKO animals (Figure 1e). Thereafter, 
simultaneous immunostaining was also performed with anti-GS to label the PGBs and with 
NeuN antibody, which labels the perikarya of neuronal cells. These immunostainings 
confirmed that the hippocampal and cortical PGBs in malinKO mice that differ from astrocytic 
CAL granules are located inside the neuronal soma, near to the neuronal nuclei (Figure 2b 
and 2e). As these granules are exclusive to the malinKO mice (the model of LD) and are 
formed in neurons, we will refer to them as neuronal Lafora bodies (nLBs). CAL granules, 
visible in the SAMP8, malinKO and control animals with the anti-GS staining, did not 
colocalize with the neuronal NeuN staining. 
 
To compare the size of astrocytic CAL granules with that of nLBs in malinKO mice, the size 
of the granules from the cortical region was measured on representative images from 
sections stained with PAS and obtained from four  malinKO animals. A total of 259 CAL 
granules and 167 nLBs were measured. Thereafter, ANOVA was performed considering 
“size of granules” as the dependent variable, “type of granule” (nLB or CAL granule) as 
independent variable defined as a fixed factor and “animal” as independent variable defined 
as random factor. ANOVA indicated that the variable “type of granule” had a significant 
effect on “size of granules”, while the variable “animal” and the interaction between the 
independent variables did not. The mean size (±SEM) of CAL granules was 1.59 (±0.03) 
µm, while that of nLBs was 2.82 (±0.08) µm (Figures 3a and 3b). These observations allow 




In the case of malinKO mice, we also determined the density of CAL granules and nLBs in 
the hippocampus and cortex of four animals. Thereafter, ANOVA was performed 
considering “density of granules” as the dependent variable and “type of granules” (CAL or 
nLBs), “brain region” (hippocampus or cortex) and “animal” as independent variables. The 
variables “type of granules” and “brain region” were defined as fixed factors and “animal” as 
random factor. The ANOVA indicated that the variables “type of granules” and “brain 
region” and the interaction between them had a significant effect on “density of granules”. 
The mean density (±SEM) of the CAL granules in the cortex and hippocampus was 4936.45 
(±594.91) granules/mm3 and 176709.32 (±16058.40) granules/mm3 respectively, and the 
mean density (±SEM) of nLBs in the cortex and hippocampus was 33671.06 (±2217.18) 
granules/mm3 and 9324.92 (±592.69) granules/mm3, respectively (Figure 3d). Post hoc 
comparisons indicated that the density of CAL granules was higher in the hippocampus 
than in the cortex, the density of nLBs was higher in the cortex than in the hippocampus, 
the density of CAL granules in the hippocampus was higher than that of nLBs in the 
hippocampus, and the density of nLBs in the cortex was higher than the density of CAL 
granules in the cortex. These results indicate that CAL granules predominate in the 
hippocampus while nLBs predominate in the cortex. Of note is the high density of CAL 
granules in the hippocampus compared to the other densities measured. 
 
As CAL granules are also present in SAMP8 and control animals, we also determined the 
density of astrocytic CAL granules in each brain region in these mouse strains. In this case, 
ANOVA was performed considering “density of granules” as the dependent variable and 
“strain” (SAMP8, malinKO and control) and “brain region” (hippocampus or cortex) as the 
independent variables, defined as fixed factors. ANOVA indicated that the variables “strain” 
and “brain region” had a significant effect on “density of granules” and the interaction 
between both variables is also significant. In SAMP8 animals, the mean density (±SEM) of 
the CAL granules in the hippocampus was 27560.24 (±1742.26) granules/mm3. In malinKO 
animals, as indicated before, the mean density (±SEM) of CAL granules in the cortex and 
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hippocampus was 4936.45 (±594.91) granules/mm3 and 176709.32 (±16058.40) 
granules/mm3, respectively. In control animals, the mean density (±SEM) of CAL granules 
in the hippocampus was 2388.17 (±428.63) granules/mm3. CAL granules were not 
observed in the cortex of SAMP8 or control animals. Histograms of mean densities are 
shown in Figure 3e. The results indicate that the density of CAL granules was higher in the 
hippocampus than in the cortex in all the mouse strains and that the density of CAL 
granules was higher in malinKO and SAMP8 animals than in controls, being also higher in 
malinKO than in SAMP8 mice. Thus, we can assume that the absence of malin in malinKO 
animals enhances the formation of CAL granules, although this increase can also be 
observed in other conditions like senescence, as observed in SAMP8 animals. 
 
Taken together, these observations indicate that malinKO animals present two types of PGB: 
a) CAL granules, which tend to form clusters, are associated with astrocytes, and 
predominate in the hippocampus, although some clusters can also be observed in the 
cortex; and b) nLBs, which are larger than CAL granules, are isolated granules, are related 
to neurons, and are found in the brain cortex and the pyramidal layer of the hippocampus. 
Of note, nLBs were exclusive to malinKO mice, while astrocytic CAL granules, which were 
also present in SAMP8 and in control animals, were enhanced in both malinKO and SAMP8 
animals. These results are summarized in Table I. 
 
Astrocytic CAL granules, but not nLBs, carry neo-epitopes recognized by natural IgMs  
Human CA, as well as CAL granules of SAMP8 and ICR-CD1 mice, contain neo-epitopes 
that can be recognized by natural IgMs (Augé et al., 2017; Manich et al., 2015). To analyze 
whether PGBs from malinKO mice also carry these neo-epitopes, double immunostaining 
was performed with anti-GS and purified human IgMs in the first incubation and the 
fluorochrome-labeled respective isotype specific antibodies in the second one. As 
expected, astrocytic CAL granules were immunostained with both antibodies, thereby 
revealing the presence of neo-epitopes on these structures (Figure 4a). In contrast, nLBs 
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were not positive for IgMs, thus indicating the absence of neo-epitopes (Figure 4b). All 
together, these observations reveal that the two types of PGB found in malinKO animals 
differ in terms of neo-epitope presence. 
 
Polyglucosan structure of CAL granules is required for the presence of the neo-epitopes 
The brains of MGSKO mice do not present PGBs and, consequently, MGS activity is a 
requisite for the formation of these bodies (Sinadinos et al., 2014; Duran et al., 2014). 
Accordingly, we examined whether the absence of the astrocytic CAL granules in MGSKO 
animals (76-80 weeks-old) correlated with the absence of the neo-epitopes. Accordingly, 
we immunostained brain sections from MGSKO animals with both anti-GS antibody and 
human IgMs. As expected, CAL granules were not detected with the anti-GS antibody in 
any brain region. Moreover, staining with human IgMs did not reveal the presence of neo-
epitopes either (Figure 5). These results suggest that the neo-epitopes are part of the 
polyglucosan structure of the PGBs or that this polyglucosan structure is required for the 
addition of components that carry the neo-epitopes. 
 
PTGOE mice present CAL granules but not nLBs 
PTG is a protein that orchestrates the signaling of several metabolic enzymes involved in 
glycogen synthesis. In this regard, the brains of PTGOE mice show enhanced PGB 
accumulation (Duran et al., 2014). We therefore examined the nature of these PGBs and 
the presence of neo-epitopes on them. Double immunostaining with both the anti-GS 
antibody and human IgMs in brain sections of PTGOE mice aged 60-64 weeks showed the 
presence of CAL granules, forming the characteristic clusters. These granules were 
immunostained with both anti-GS antibody and human IgMs and were located mainly in the 
hippocampus (Figure 6). No nLBs were found in this mouse model. Based on these 
observations, we postulate that the overexpression of PTG is not sufficient to trigger the 





p62 is present in both CAL granules and nLBs 
p62 is an ubiquitin-binding scaffold protein that interacts with ubiquitinated proteins via its 
C-terminal ubiquitin-associated (UBA) domain. The direct binding of p62 to LC3 and 
GABARAP family proteins, that serves as membrane linked protein-binding platforms (Qiu 
et al., 2017), allows p62 to guide ubiquitinated proteins to autophagosomes and to 
autophagic processes (Isakson et al., 2013). Moreover, p62 is also related to secretory 
autophagy, in which the content of the autophagosome is extruded from the cell (Ponpuak 
et al., 2016). Impaired autophagy has been described in LD mouse models, and it has been 
reported that p62 is increased in the brains of malinKO mice (Duran et al., 2014). To 
determine whether the PGBs of malinKO mice contain this protein, we performed double 
immunostaining with anti-GS and anti-p62 antibodies on brain sections of these animals. 
Both CAL granules and nLBs were stained with anti-p62 antibody, thereby indicating the 
presence of these proteins in both types of PGB (Figure 7). The presence of p62 in nLBs, 
which are located in the neuronal soma, near the nuclei, suggests that nLBs are related to 
lysosomal degradative autophagy. CAL granules, however, are located in astrocytic 
processes. As we will further discuss, the presence of p62 in these cells is perhaps related 
to secretory autophagy. It should be noted that to avoid false staining produced by 
contaminant IgMs in the vial, in the second incubations we used specific anti-IgG secondary 
antibodies that do not recognize the IgMs. In a complementary manner, and as performed 
for the anti-GS, we also examined whether mouse IgMs were present in the vial of anti-p62 
antibody obtained in mouse. To this end, we stained some sections with anti-p62 antibody 
in the first incubation and with a secondary fluorochrome-labeled anti-mouse IgM antibody 
in the second one. The  absence of staining in CAL granules indicated that the anti-p62 vial 








LD is characterized by the accumulation of PBGs in the brain, in the form of the so-called 
LBs. Traditionally, LBs are considered to be neuronal inclusions that occur concomitantly 
with neurodegeneration and epilepsy and they are related to the inexorable worsening of 
the condition until death in early adulthood (Lafora & Glueck, 1911). The extensive neuronal 
loss and severe neuropathological phenotypes observed in patients and animal models of 
LD suggest that neurons are particularly vulnerable to excess glycogen accumulation 
(Delgado-Escueta, 2007; Duran et al., 2014; López-González et al., 2017; Vallés-Ortega et 
al., 2011). Consistent with this, we have demonstrated that glycogen accumulation in 
neurons induces their death by apoptosis (Duran et al., 2012). 
 
In this study, however, we demonstrate that malinKO mice present high numbers of two 
types of PGB in the brain, one affecting neurons (nLBs) and the other astrocytes (CAL 
granules). The CAL granules, referred to in some cases as “PAS granules” in the literature, 
are also abundant in SAMP8 mice and in aged mice of other strains (Akiyama et al., 1986; 
Jucker et al., 1994b; Kuo et al., 1996; Manich et al., 2011; Manich et al., 2014a). We 
observed that the number of CAL granules was also increased in PTGOE mice, indicating 
that the enhanced activity of MGS promotes their formation. Also, we found that CAL 
granules were absent in MGSKO animals, thereby indicating that the synthesis of glycogen 
is indispensable for their formation. In a recent study, Oe et al. (2016) found that levels of 
glycogen from young C57BL/6 mice were high in the hippocampus. The accumulation of 
this glycogen was mainly in astrocytes, predominantly in their processes. In addition, these 
cells showed a patchy distribution of glycogen, each patch corresponding to an individual 
astrocyte. This patchy distribution diminished in aged mice, when PGBs appeared. The 
results obtained in the study by Oe et al. are thus consistent with our work, considering that 
the shifting from patchy glycogen to aberrant polyglucosan that forms the PGBs could be 
enhanced in malinKO, PTGOE and SAMP8 but not in MGSKO animals. The other type of PGB 
that we found in malinKO mice, located in the perikarya of the neurons, near to neuronal 
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nuclei, and referred to here as nLBs, appears to be exclusive to this animal model since it 
has not been observed in any other strain. All together, these results indicate that the 
absence of malin triggers the formation of PGBs in neurons and enhances the development 
of these bodies in astrocytes. 
 
Accordingly, although it is widely assumed that all the PGBs in the brains of LD patients are 
neuronal, we propose that the two types of PGB described here are present: one type, 
probably CA, derived from astrocytes and the other type derived from neurons. Therefore, 
the term LBs should be limited to refer to nLBs. Moreover, based on the observations made 
in the malinKO mouse model, the amount of the different types of PGB in the brains of LD 
patients is expected to be dependent on the brain region. The probable significant presence 
of both types of PGB in the brains of these individuals reinforces the need to make a 
distinction between LBs and CA, as previously stressed by various authors (Cervós-
Navarro, 1991; Leel-Ossy, 2001; Ramsey, 1964; Seitelberger, 1968; Yoshimura, 1977). 
 
As indicated earlier, we previously described the presence of neo-epitopes on both CAL 
granules from mouse brains and CA from human brains (Augé et al., 2017; Manich et 
al.,2014b). Although the composition of CA must be re-examined due to the possible false 
positive staining in immunohistochemical studies (Augé et al., 2017), there is wide 
consensus that CA contain waste products (Cavanagh, 1999; Pirici and Margaritescu, 
2014) and ubiquitin (Cissé et al., 1995; Day et al., 2015; Pirici et al., 2014; Pirici and 
Margaritescu, 2014; Wilhelmus et al., 2011). It has been proposed that the presence of 
neo-epitopes on CA is related to the removal of these bodies via the natural immune 
system after their extrusion (Augé et al., 2017). In this regard, here we show that CAL 
granules contain p62 protein, which has a ubiquitin-binding domain and is involved in the 
sequestration of ubiquitinated proteins and organelles (Liu et al., 2016). Also, p62 is related 
to secretory autophagy, a process in which the content of the autophagosome extrudes 
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from the cell (Ponpuak et al., 2016). Therefore, the presence of p62 in CAL granules is 
consistent with the extrusion of CA from human brains.  
 
Furthermore, the presence of a high number of CAL granules in the malinKO mouse model 
suggests that the absence of malin alters glycogen metabolism not only in neurons but also 
in astrocytes. In the case of PTGOE mice, CAL granules, but not nLBs, are also present in 
high numbers. This observation thus indicates distinct routes or key regulators in the 
genesis of nLBs and CAL granules. However, the activity of MGS is required for the 
formation of both types of granule, as can be deduced from the observation that CAL 
granules are absent in MGSKO animals and that both types of PGB are absent in the double 
mutant malinKO+MGSKO mouse (Duran et al., 2014). CAL granules differ from nLBs in terms 
of distribution in the brain, size, clustering, and presence of neo-epitopes recognized by 
IgMs. We previously described the presence of PGBs in astrocytes of the malinKO mouse 
model (Valles-Ortega et al., 2011). In the present work, we identify astrocytic PGBs as CAL 
granules and an important pool of PGBs in LD. Since astrocytes serve essential roles in 
brain function, the impairment of astrocytic activity caused by the accumulation of CAL 
granules may contribute to the pathophysiology of LD. In this regard, astrocytic uptake of 
potassium and glutamate is essential for the regulation of neuronal excitability, and the 
malfunction of astrocytes in LD could explain the epileptic phenotype of the disease 
(Amédée et al., 1997; Coulter and Eid, 2012). Given that aged mice and the PTGOE mouse 
model show increased accumulation of CAL granules, it would be of interest to study the 
epileptic phenotype of these animals. 
 
LBs have been classified as type I or type II on the basis of their size and shape (Van Hoof 
et al., 1967; Machado-Salas J et al., 2012). Furthermore, it has been hypothesized that 
these two types are different stages of the same process, in which the accumulation of type 
I LBs would activate the formation of type II LBs (Machado-Salas et al., 2012). On the basis 
of the results and images presented in that study, it seems that type I LBs correspond to 
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CAL granules and type II to nLBs. Therefore, if this correspondence is correct, it is not 
possible that type I LBs would activate the formation of type II, because of the different 
cellular origin and different brain region preferences of CAL granules and nLBs. Moreover, 
given the presence of possible IgM contaminants in the antibodies used and the false 
staining that IgMs can produce (Manich et al., 2015), we propose that 
immunohistochemistry studies of PGBs should be reanalyzed. 
 
In conclusion, here we report that the absence of malin enhances the formation of 
astrocytic CAL granules and triggers the formation of nLBs. These findings should be 
considered when studying LD, and further work should be done to determine the 
involvement of each type of PGB in the etiopathogeny of this disease. Greater knowledge 
of the effects of CAL granules on astrocytes and those of nLBs on neurons, as well as the 
interaction between the neo-epitopes present in CAL granules and the natural immune 
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Figure 1. PGBs associated with astrocytes in SAMP8, malinKO and control animals. 
Representative images of hippocampal and cortical brain sections from SAMP8, malinKO 
and control mice double immunostained with anti-GS (red) and anti-GFAP (green) 
antibodies. Hoechst (blue) was used for nuclear staining. Hippocampal brain sections from 
SAMP8, malinKO mice, and, sporadically, control mice, show clusters of astrocyte-
associated CAL granules (arrows in a1, b1 and c1). In some cases, the whole astrocyte 
involved in the formation of a cluster of CAL granules can be observed (a2, b2 and c2). 
MalinKO mice also present some non-astrocyte-associated PGBs (arrowheads), located 
mainly in the pyramidal layer (pl) of the hippocampal CA3 region (b1 and b3). These non-
astrocyte-associated PGBs are not detected in SAMP8 or control animals (a3, c3). Cortex 
brain sections from malinKO mice also contain non-astrocyte-associated PGBs (arrowheads 
in e1), which are located near to some nuclei (e2), and only a few clusters of CAL granules 
(e3). The cortex of SAMP8 and control animals do not show PGBs (d1, d2, f1 and f2). 
Arrows: clusters of astrocyte-associated CAL granules. Arrowheads: non-astrocyte-
associated PGBs. Scale bar a1-f1: 100 µm; a2-f2, a3-c3 and e3: 20 µm. 
 
 
Figure 2. PGBs associated with neurons in malinKO animals. Representative images of 
hippocampal and cortical brain sections from SAMP8, malinKO and control mice double 
immunostained with anti-GS (green) and NeuN (red) antibodies. Hoechst (blue) was used 
for nuclear staining. MalinKO mice show neuronal PGBs (arrowheads in b1 and b3) and 
clusters of CAL granules (arrows in b1 and b2) in the hippocampus. Neuronal PGBs are 
mainly in the pyramidal layer. Hippocampal sections of SAMP8 mice show CAL granules 
(a1 and a2).  Clustered CAL granules are also observed in control animals (c1 and c2), but 
in low numbers. Neither SAMP8 or control mice show neuron-associated PGBs in the 
hippocampus (a3 and c3). Neuron-associated and some non-neuron-associated PGBs can 
be observed in the cortex of malinKO animals (e1, e2 and e3). No PGBs were observed in 
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the cortex of SAMP8 or control animals (d1, d2, f1 and f2). As neuronal PGBs are exclusive 
to the malinKO mouse, a model of Lafora disease, and they are found in neurons, they are 
referred to as neuronal Lafora bodies (nLBs). Arrows: clusters of CAL granules. 
Arrowheads: nLBs. pl: pyramidal layer of the hippocampus. Scale bar a1-f1: 100 µm; a2-f2, 
a3-c3 and e3: 20 µm. 
 
Figure 3. CAL granules, smaller than nLBs, predominate in the hippocampus while 
nLBs predominate in the cortex. (a) Representative image of the cortex of a malinKO 
mouse immunostained with PAS, in which nLBs (arrowheads) and a cluster of CAL 
granules (arrow) can be observed. (b) Histogram showing the mean diameter (and SEM) of 
nLBs and CAL granules in the cortex of malinKO mice. (c) Representative images of the 
hippocampus and cortex of SAMP8, malinKO and control mice. Clusters of CAL granules 
can be observed in the hippocampus of all animals. Some clusters of CAL granules are 
also observed in the cortex of malinKO mice, which also includes nLBs (see detail in image 
a). (d) Histogram showing the density of CAL granules and nLBs in the hippocampus and 
cortex of malinKO animals. (e) Histogram showing the density of CAL granules in the 
hippocampus and cortex of SAMP8, malinKO and control animals. All histograms express 
the mean and SEM, and significant differences are detailed in the text. Scale bars: 100 µm.  
 
Figure 4. CAL granules, but not nLBs, contain neo-epitopes. Representative images of 
hippocampal (a1-a3) and cortex (b1-b3) regions of malinKO mice double immunostained 
with anti-GS antibody (red) and IgMs (green). Hoechst (H, blue) was used for nuclear 
staining. A cluster of CAL granules from the hippocampus is stained with GS (a1) and also 
with IgMs (a2). Colocalization (yellow to orange) can be observed in the merged image 
(a3), indicating that CAL granules contain neo-epitopes. PGBs associated with neurons 
(nLBs) are stained with anti-GS antibody (b1) but not with the IgMs (b2). The absence of 




Figure 5. GS is necessary for the detection of clusters of granules containing neo-
epitopes. Representative images of hippocampal and cerebral cortex regions of MGSKO 
mice double immunostained with anti-GS antibody (red) and IgMs (green). Hoechst (H, 
blue) was used for nuclear staining. The absence of clusters of granules containing neo-
epitopes indicate that the glycosidic structure of CAL granules is necessary for the 
presence of these epitopes. Scale bar a1 and b1: 200 µm; a2 and b2: 100 µm. 
 
Figure 6. PTGOE animals present CAL granules but not nLBs. Representative images of 
hippocampal and cerebral cortex regions of PTGOE mice double immunostained with anti-
GS antibody (red) and IgMs (green). Hoechst (H, blue) was used for nuclear staining. CAL 
granules stained with anti-GS antibody (a1) and IgMs (a2) can be observed in the 
hippocampus, and they are also visible in the merged image (a3). These animals, however, 
do not present nLBs, as can be seen in cortex images stained with anti-GS antibody (b1) 
and IgMs (b2) or in the merged image (b3). Scale bar: 100 µm. 
 
Figure 7. Autophagy marker p62 is present in both CAL granules and nLBs. 
Representative images of hippocampal and cerebral cortex regions of malinKO mice double 
immunostained with anti-GS (green) and anti-p62 (red) antibodies. Hoechst (H, blue) was 
used for nuclear staining. CAL granules and nLBs stained with both anti-GS (a1) and anti-
p62 (a2) antibodies can be observed in the hippocampus. nLBs, also stained with anti-GS 
(b1) and anti-p62 (b2) antibodies, can also be seen in the cortices of the animals. Both 
types of granules can be also appreciated in the merged images (a3, b3). These results 
indicate that both types of PGB contain the p62 autophagy marker. pl: pyramidal layer of 





Figure S1 (Supplementary material). Example of image processing to quantify 
granules using the ImageJ program. a) Original image from a cortical region of a malinKO 
mouse stained with PAS, in which the granules present in the cluster (arrow) were 
quantified. b) Image of the green channel transformed to 8 bits, obtained after splitting the 
color channels. c) Binarized image after establishing the threshold. d) Binarized image after 
applying the watershed, in which some fused granules become separated (see insets in c 
and d). e) The region of interest (ROI) is defined in the original image; in this example, the 
ROI contains only one cluster of granules. f) Image showing the granules that were 
detected by analyzing the particles on the image d after applying the ROI defined in image 
e. In this case, 48 granules were detected. 
 
 
Figure S2 (Supplementary material). The vials of GS and p62 antibodies do not 
contain contaminant IgMs. Representative images of hippocampal regions of malinKO 
mice immunostained with a) primary antibody anti-GS and secondary antibody AF555 anti-
IgG (red staining), b) anti-GS and FITC anti-IgM (green staining), c) anti-p62 and AF555 
anti-IgG (red staining), and d) anti-p62 and AF488 anti-IgM (green staining). Hoechst (blue) 
was used for nuclear staining. CAL granules are not stained when secondary anti-IgM 
antibody is used, indicating the absence of IgM contamination, while they are stained when 







Table I. Type and features of PGBs present in each strain or transgenic mouse model  
 
 Type of PGBs Formed in 
Presen-
tation 
Density1 in Cx 
(PGBs/mm3) 
Density1 in Hc 
(PGBs/mm3) 















C57BL/6 CAL astrocytes clustered --- 2388.17 (±428.63) --- present 
SAMP8 CAL astrocytes clustered  --- 27560.24 (±1742.26) --- present 
PTGOE CAL astrocytes clustered n.a. n.a. n.a. present 





PGBs: polyglucosan bodies; nLBs: neuronal Lafora bodies; CAL: corpora amylacea-like 
granules; Hp: hippocampus; Cx: cerebral cortex. --- indicates absence of granules. n.a.: 
data not available. 1 expressed as mean (± standard error of the mean).  
 
 
 
